Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19697160 | 0.98 | DAO (0.47) | DAOTDP1L3MBTL1CYP11B1CYP11B2 | |
| SCHEMBL20392647 | 0.98 | DAO (0.47) | DAOTDP1L3MBTL1CYP11B1CYP11B2 | |
| SCHEMBL11973910 | 0.87 | DAO (0.51) | DAOCYP11B1CYP11B2GABRA2GABRB2 | |
| SCHEMBL27733869 | 0.81 | TDP1 (0.59) | TDP1L3MBTL1PTGS2CYP3A4 | |
| SCHEMBL9610936 | 0.80 | DAO (0.46) | DAOCYP11B1CYP11B2 | |
| SCHEMBL14402519 | 0.80 | PTGS2 (0.50) | DAOPTGS2CYP3A4GABRA2GABRB2 | |
| Hydrochloric Acid SCHEMBL28015977 | 0.79 | TDP1 (0.57) | TDP1L3MBTL1PTGS2CYP3A4 | |
| SCHEMBL27563659 | 0.79 | TDP1 (0.57) | TDP1L3MBTL1PTGS2CYP3A4 | |
| SCHEMBL27567833 | 0.78 | PTGS2 (0.52) | PTGS2CYP3A4GABRA2GABRB2TRPV1 | |
| SCHEMBL19619535 | 0.77 | TDP1 (0.50) | TDP1L3MBTL1PTGS2CYP3A4TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | ADORA2A, ADORA2B, ADORA3 | DAO 724/4885TDP1 3195/4885L3MBTL1 4512/4885 |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | DAO 1253/4885TDP1 3884/4885L3MBTL1 4819/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | DAO 1253/4885TDP1 3884/4885L3MBTL1 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.